What Lenvima (Lenvatinibum) Treats: Main Uses and Benefits

The therapeutic role of Lenvatinib is used for managing systemic disease control in adults diagnosed with specific advanced cancers. It is applied in clinical settings where the malignancy is progressive, recurrent, or is considered resistant to prior standard treatments. Lenvatinib is considered relevant for the management of specific advanced malignancies.

The medication is commonly used to address conditions presenting with significant systemic or localized discomfort. It is primarily applied for Differentiated Thyroid Carcinoma (DTC) that no longer responds to radioactive iodine, Hepatocellular Carcinoma (HCC) that is unresectable, and advanced Renal Cell Carcinoma (RCC) and Endometrial Carcinoma (EC). Its core benefit is that it may assist with slowing cancer advancement, contributing to maintaining the duration of disease stability and helping to ease the overall symptom load.

---

Quick Fact: Relief for Advanced Cancer Symptoms

Property	Description
Core Therapeutic Role	Used for managing systemic control of advanced, progressive malignancies
Typical Scenario	Disease that is unresectable, metastatic, or resistant to prior therapy
Primary Benefit	Supports the duration of disease stability and general well-being
Symptom Management	Assists with symptoms related to physical discomfort and systemic functional stress

Lenvima is indicated for adult patients with approved malignancies. The safety and effectiveness of the medicine have not been established in pediatric patients under 18 years of age, and use is generally not recommended for children.

---

The medicine is prohibited for use in pregnant women due to the documented risk of fetal harm. Females of reproductive potential must use effective contraception throughout therapy and for 30 days following the final dose. Breastfeeding is not recommended and must be discontinued for at least one week after the final dose.

Eligibility is also conditional on the patient's existing health status. Patients with severe kidney impairment or severe hepatic impairment (Child-Pugh C) are eligible, but require a reduced starting dose for certain indications. Uncontrolled high blood pressure must be well controlled before treatment initiation. Lenvima has not been studied, and no recommended dose is available, for patients with end-stage renal disease (ESRD) or those with severe hepatic impairment for the hepatocellular carcinoma indication.

Lenvatinib’s official interaction profile is defined by its metabolic pathways and transporter status, in addition to one key pharmacodynamic risk. Regulatory documents state that Lenvatinib is primarily metabolized by the hepatic enzyme CYP3A4 and functions as a substrate for the drug efflux transporters P-glycoprotein (P-gp) and BCRP.

Pharmacokinetic Interactions

Co-administration with potent inhibitors of CYP3A4, P-gp, and BCRP, such as Ketoconazole, is documented to increase Lenvatinib's systemic plasma exposure (AUC and Cmax). Conversely, exposure may be decreased when combined with potent inducers of CYP3A4 and P-gp, such as multi-dose Rifampicin.

Pharmacodynamic and Condition-Specific Notes

No formal contraindications are listed in the official labeling. A pharmacodynamic interaction risk exists with co-administration of other medicinal products known to prolong the QTc interval, potentially leading to an additive effect on QTc prolongation.

Lenvatinib exposure is documented to be increased in individuals with severe hepatic impairment (Child-Pugh C) and severe renal impairment ( CrCl < 30 mL/min) due to reduced clearance. The official labels specify no clinically significant interaction with food, allowing administration with or without a meal, and list no mandatory time separation rules for other medicines.

Lenvatinib functions as a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor. Its core mechanism involves competitive binding to the internal ATP-binding pocket of several key receptors, including the entire Vascular Endothelial Growth Factor Receptor (VEGFR) family (1, 2, and 3) and all four subtypes of Fibroblast Growth Factor Receptor (FGFR). It also targets PDGFRalpha, KIT, and the RET proto-oncogene.

By blocking ATP access, Lenvatinib prevents the necessary autophosphorylation of these receptors, thereby shutting down the downstream signaling cascades that promote cell growth and survival. The inhibition of VEGFRs blocks signals that govern endothelial cell migration and proliferation, resulting in the suppression of pathogenic blood vessel formation (anti-angiogenesis). Simultaneously, the blockade of FGFRs, RET, and KIT directly suppresses aberrant cell division signals within pathological cells.

This combined physiological action restricts the ability of pathological cells to expand by disrupting both the vascular supply and intrinsic growth signals. This mechanism is subject to constraint by acquired resistance, where pathological cells activate alternative signaling pathways, functionally overriding Lenvatinib's inhibition and limiting the sustained physiological effect of growth restriction.

Lenvima is an oral medication supplied as a hard capsule, intended for once-daily administration. To maintain consistent drug levels, Lenvatinib should be taken at approximately the same time each day, and it may be consumed with or without food.

The starting dose for Lenvatinib is customized based on the specific cancer indication being treated. For example, the monotherapy starting dose for Differentiated Thyroid Carcinoma (DTC) is 24 mg once daily, while combination therapy for Renal Cell Carcinoma (RCC) or Endometrial Carcinoma (EC) typically begins with 20 mg of Lenvatinib once daily. Certain combination therapies also involve an accompanying medication administered via intravenous infusion.

---

Administration and Dose Adjustment

The hard capsules must be swallowed whole with water. If a patient is unable to swallow the capsules, the daily dose may be prepared as an oral suspension by dissolving the capsules in a small amount of water or apple juice. If a dose is missed, and the time until the next scheduled dose is less than 12 hours, the missed dose should be skipped.

Treatment is generally continued until the disease progresses. The dose is subject to downward adjustment for tolerability but is not increased above the initial prescribed dose. Furthermore, patients with severe renal or hepatic impairment require a lower initial starting dose than those with normal function.

Research evidence / Overview of studies for Lenvima (Lenvatinibum)

Evidence for use in Differentiated Thyroid Carcinoma (DTC)

Research evidence for Lenvatinib in advanced, radioactive iodine-refractory DTC includes large-scale, randomized, placebo-controlled trials. These studies were applied in populations of adults whose disease had progressed despite prior treatment. Researchers examined outcomes related to Progression-Free Survival (PFS), which tracks the time during which the disease remains stable, and Objective Tumor Response Rate (ORR). Data related to Overall Survival (OS) was also tracked; however, treatment crossover is a documented factor that may affect the interpretation of the Overall Survival analysis. Evidence highlights that many patients required dose interruptions or reductions during the study period.

Evidence for use in Hepatocellular Carcinoma (HCC)

Research for unresectable HCC includes a Phase 3 randomized, non-inferiority trial designed to evaluate Lenvatinib against an active comparator. Studies monitored Overall Survival (OS) with the goal of determining if the outcomes tracked with those of the active comparator. Research reported that Overall Survival measurements were similar between the two treatment groups. A limitation of the study design is that it specifically set out to show non-inferiority for OS, not to establish a statistically superior outcome. Data for patients with more severe liver impairment remains insufficient.

Evidence for use in Advanced Renal Cell Carcinoma (RCC)

Research explored Lenvatinib in different combination regimens, depending on prior treatment. For first-line treatment, evidence is based on large, randomized, open-label trials that examined PFS, OS, and ORR compared to standard monotherapy. For post-prior-therapy use, the data is derived from smaller Phase 2 trials, where limited information is available compared to the large Phase 3 studies. Trial data indicated that frequent dose interruption or reduction was required across the combination regimens.

Long-Term Follow-up and Remaining Research Gaps

Across the indications, studies monitored the Duration of Response (DOR) to provide context on how long a response was maintained. For certain indications, long-term follow-up extending for several years has been reported. However, the long-term effects are not fully established beyond the defined observation periods of the clinical trials. Research highlights that the full impact of dose adjustments on final, long-term patient outcomes is not fully characterized.

Key Studies & References

1. Lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial carcinoma (KEYNOTE-775/ENGOT-en9): an open-label, randomised, phase 3 trial (EC Evidence)

Common questions about Lenvima (Lenvatinibum) (FAQ)

---

Q: What specific types of cancer is Lenvima approved to treat?

Lenvima is officially approved to treat adults with certain types of differentiated thyroid carcinoma (DTC), hepatocellular carcinoma (HCC), and renal cell carcinoma (RCC). Official product information also notes its use in combination with another medicine for certain types of advanced endometrial carcinoma (EC).

---

Q: Is Lenvima ever used in combination with other treatments?

Yes, regulatory documents confirm that Lenvima is approved to be used as part of a combination therapy for specific conditions. This includes its use with another medicine for certain cases of advanced renal cell carcinoma (RCC) and advanced endometrial carcinoma (EC).

---

Q: Is Lenvima approved for use in combination with pembrolizumab (Keytruda) for any conditions?

Yes, official prescribing information states that Lenvima is approved for use in combination with pembrolizumab (which is sold under the brand name Keytruda) for certain types of advanced endometrial carcinoma.

---

Q: Are there published studies showing the long-term effects of Lenvima treatment?

Studies and official information indicate that clinical trials report a defined follow-up time for patients, often tracking outcomes like Progression-Free Survival and Overall Survival. While long-term follow-up extending for several years has been reported for some indications, the long-term effects are not fully established beyond the observation periods of the clinical trials.

---

Q: Can Lenvima cause issues with the heart or blood vessels?

Official safety information notes potential risks to the cardiovascular system. These include cardiac dysfunction and the risk of arterial thromboembolic events, which are described as serious events like stroke or heart attack. Regulatory notes also emphasize monitoring of the heart's electrical activity (QT interval).

---

Q: What is the 'Reversible Posterior Leukoencephalopathy Syndrome (RPLS)' mentioned in the safety information?

Official information states that RPLS has been reported with Lenvima use. This syndrome affects the brain, and symptoms such as seizures, headache, visual disturbances, confusion, or altered mental function are noted as reasons to consider this syndrome.

---

Q: Why is blood pressure monitoring so important while taking Lenvima?

The use of Lenvima may commonly cause or worsen hypertension (high blood pressure). Because uncontrolled high blood pressure can lead to other serious risks, such as stroke, heart attack, or kidney impairment, control and regular monitoring of blood pressure are key recommendations found in official safety notes.

---

Q: Can Lenvima cause problems with wound healing after surgery?

Yes, official safety information includes a warning about the potential for impaired wound healing while taking Lenvima. For this reason, regulatory documents recommend withholding treatment for a duration of time both before and after major surgery.

---

Q: Are there specific criteria, like tumor type or genetic markers, that determine eligibility for Lenvima?

Yes, in addition to general health status, official criteria include specific characteristics of the tumor. For example, for differentiated thyroid cancer, the tumor must be radioactive iodine-refractory. For the advanced endometrial carcinoma combination, specific molecular features must be absent.

---

Q: Does Lenvima interact with common blood thinners or anti-coagulation medicines?

The official safety warning advises caution when Lenvima is used with any medicine that increases the risk of bleeding, such as anti-coagulation medicines (blood thinners). This is because Lenvima itself carries a risk of hemorrhagic events (bleeding problems).

---

Q: Is Lenvima considered appropriate for patients of all ages, including the elderly?

Lenvima is generally indicated for adult patients. While clinical trials included patients over 65, official information notes that adverse reactions were more frequent in patients aged 75 and older. The medication is generally not recommended for children under the age of 18.

---

Q: What are the most common gastrointestinal side effects of Lenvima?

According to official product information, diarrhea is classified as a very common gastrointestinal side effect of Lenvima. Other commonly reported gastrointestinal effects include abdominal pain and a decreased appetite.

---

Q: What is the reason Lenvima is sometimes combined with everolimus?

The combination of Lenvima and everolimus is approved for advanced renal cell carcinoma (RCC). Clinical trial data reviewed by regulatory bodies demonstrated that this combination provided a significantly longer Progression-Free Survival (PFS)—meaning more time without the disease getting worse—compared to everolimus alone.

---

Q: What is the definition of a 'complete response' versus a 'partial response' in Lenvima clinical trials?

Clinical trials measure outcomes using standardized criteria. A Complete Response (CR) is defined as the disappearance of all signs of the cancer that could be measured. A Partial Response (PR) is defined as a specific, measurable decrease in the size of the tumors being tracked.

---

Q: What does the term 'progression-free survival' mean in Lenvima research?

Progression-Free Survival (PFS) is a time-based measurement used in clinical studies and research summaries. It tracks the total length of time from the start of the treatment until the disease shows evidence of getting worse (progressing) or until death occurs.

---

Q: Can Lenvima affect fertility in men or women?

Official prescribing information indicates Lenvima may impair fertility in both women and men. This potential is based on observations from animal studies, which noted effects on the ovaries and other reproductive organs.

---

Q: How long does the effect of Lenvima last after the last dose?

The time it takes for the amount of Lenvatinib in the body to decrease by half (half-life) is approximately 28 hours. This pharmacological measurement provides context on the drug's duration and how long it remains in the system.

---

Q: Does Lenvima cause low blood calcium levels (hypocalcemia)?

Yes, official safety information indicates that hypocalcemia (low blood calcium levels) has been reported in patients using Lenvima. Regulatory documents note that blood calcium levels should be monitored regularly during treatment.

---

Q: Why is there a warning about bleeding problems with Lenvima?

A warning about hemorrhagic events (bleeding problems) exists because serious and sometimes fatal bleeding has been reported in clinical studies. This risk is attributed to Lenvima's mechanism of action, which involves blocking the pathways that affect the growth of new blood vessels.

---

Q: If I have a history of a blood clot, is Lenvima still an option?

The official warning advises caution and monitoring for patients who have a higher risk of developing an arterial thromboembolic event (blood clot) while taking the medication. A prior history of a blood clot is listed as a potential hazard to be considered before and during treatment.

---

Q: Does Lenvima have different approved uses in other countries compared to the United States?

Regulatory bodies like the EMA and FDA independently authorize specific indications for Lenvima. While the core uses often overlap, the precise details of approved uses, combinations, or specific patient populations may differ based on the individual regulatory decisions made in various countries.

Official Storage and Handling Requirements

Lenvima hard capsules must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted to 30 C (86 F) [Source: FDA, EMA]. The product should be kept in the original container and must be stored out of the reach and sight of children. Do not crush or break the capsules.

Stability and Disposal

Product Form	Storage Temperature	Maximum Stability Limit
Capsules	20 C to 25 C	Determined by Expiration Date
Prepared Suspension	Refrigerated (2 C to 8 C)	24 hours

Any prepared liquid suspension must be discarded if not used within 24 hours of mixing. Unused or expired capsules should not be flushed down a toilet or placed in household drains, but must be disposed of according to local pharmaceutical waste programs.